Pharmacokinetics of drugs in spontaneously or secondary hypertensive rats

References

• Aotake T, Lu CD, Chiba Y, et al. (1999). Changes of angiogenesis and tumor cell apoptosis during colorectal carcinogenesis. Clin Cancer Res 5:135–42
   PubMedGoogle Scholar
• Bener A, Al-Ansari A, Afifi M, Krishna PV. (2007). Erectile dysfunction among hypertensive men in a rapidly developing country. Indian J Urol 23:109–13
   PubMedGoogle Scholar
• Benet LZ, Hoener B-a. (2002). Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115–21
   PubMed Web of Science ®Google Scholar
• Berecek KH, Barron KW, Webb RL, Brody MJ. (1982). Vasopressin-central nervous system interactions in the development of DOCA hypertension. Hypertension 4:II-131–7
   Google Scholar
• Bhargava HN. (1982). Pharmacological responses to acute morphine administration in normotensive Wistar–Kyoto and spontaneously hypertensive rats. Life Sci 31:2463–70
   PubMed Web of Science ®Google Scholar
• Bhargava HN, Villar VM. (1992). Pharmacodynamics and pharmacokinetics of intravenously administered morphine in spontaneously hypertensive and normotensive Wistar–Kyoto rats. J Pharmacol Exp Ther 261:290–6
   PubMedGoogle Scholar
• Boralli VB, Coelho EB, Lanchote VL. (2009). Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats. Chirality 21:886–93
   PubMedGoogle Scholar
• Chiappe de Cingolani GE. (1988). Adipocyte responsiveness to norepinephrine in spontaneously hypertensive rats. Metabolism 37:318–22
   PubMedGoogle Scholar
• Choi YM, Kim SH, Lee MG. (1991a). Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. J Pharm Sci 80:638–42
   PubMedGoogle Scholar
• Choi YM, Lee SH, Jang SH, Lee MG. (1991b). Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and the pharmacodynamics of bumetanide in rats. Biopharm Drug Dispos 12:311–24
   PubMedGoogle Scholar
• Choi YH, Lee YS, Bae SH, et al. (2009). Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats. Biopharm Drug Dispos 30:305–17
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee YS, Lee MG, et al. (2010). Pharmacokinetics of mirodenafil, a new erectogenic, and its metabolite, SK3541, in rats: involvement of CYP1A1/2, 2B1/2, 2D subfamily, and 3A1/2 for the metabolism of both mirodenafil and SK3541. J Pharm Pharm Sci 13:93–106
   PubMedGoogle Scholar
• Cloix J-F, Devynck M-A, d'Herbigny E, et al. (1982). Electrophoretical characterization of red blood cell membrane proteins and plasma protein in spontaneously hypertensive rat. Biochem Biophys Res Commun 105:1577–81
   PubMedGoogle Scholar
• Cloix J-F, Devynck M-A, Funck Brentano J-L, Meyer P. (1983). Plasma protein changes in primary hypertension in humans and rats. Hypertension 5:128–34
   PubMed Web of Science ®Google Scholar
• Czyźewska-Szafran H, Wutkiewicz M, Danysz A. (1979). Studies on the cause of changes of reactivity to hexobarbital in spontaneously hypertensive rats (SHR). Pol J Pharmacol Pharm 31:1–8
   PubMedGoogle Scholar
• Czyźewska-Szafran H, Wutkiewicz M. (1980). Pharmacodynamics and pharmacokinetics of some hypnotic drugs in spontaneously hypertensive rats (SHR). Pol J Pharmacol Pharm 32:133–9
   PubMedGoogle Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–5
   PubMed Web of Science ®Google Scholar
• Diesterhaft M. (1984). Isolation of a plasma protein elevated during hypertension in the rat. Biochem Biophys Res Commun 125:888–94
   PubMedGoogle Scholar
• Dorey PG, King J, Munday KA, et al. (1983). Intestinal fluid absorption in spontaneously hypertensive rats. J Physiol 344:1–9
   PubMedGoogle Scholar
• Duarte CG, Zhang J, Ellis S. (2001). Review of studies establishing the aging spontaneously hypertensive rat as a detector and quantifier of the kidney toxicity of radiocontrast media and other chemicals. Invest Radiol 36:56–63
   PubMedGoogle Scholar
• Ferrara N, Houck K, Jakeman L, Leung DW. (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32
   PubMed Web of Science ®Google Scholar
• Fukuda S, Tsuchikura S, Iida H. (2004). Age-related changes in blood pressure, hematological values, concentrations of serum biochemical constituents and weights of organs in the SHR/Izm, SHRSP/Izm and WKY/Izm. Exp Anim 53:67–72
   PubMed Web of Science ®Google Scholar
• Gu T-H, Zhao G-S, Zhang Z-Y, Pan W-H. (1999a). Abnormal pharmacokinetics of phenylalanine in spontaneously hypertensive rat. Chin J Pathophysiol 15:21–3
   Google Scholar
• Gu T, Zhao G, Zhang Z. (1999b). The Pharmacokinetics of phenylalanine in different hypcrtensive rats. Acta Universitatis Medicinalis Secondae Shangai 19:22–31
   Google Scholar
• Han KS, Lee SH, Lee MG, Kim ND. (1993). Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to spontaneously hypertensive rats and DOCA–salt induced hypertensive rats. Biopharm Drug Dispos 14:533–48
   PubMedGoogle Scholar
• Hara A, Yamamoto J, Matsunaga M, et al. (1977). Renal function and development of hypertension in spontaneously hypertensive rat. Jpn Heart J 18:577–8
   PubMedGoogle Scholar
• Hikida M, Kawashima K, Yoshida M, Mitsuhashi S. (1992). Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 30:129–34
   PubMed Web of Science ®Google Scholar
• Höcht C, Di Verniero C, Opezzo JAW, et al. (2006). Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study. Naunyn-Schmiedeberg’s Arch Pharmacol 373:310–18
   Google Scholar
• Isanta JR, Lasheras B, Fos D, Cenarruzabeitia E. (1987a). Comparative diltiazem plasma clearance in normotensive and hypertensive rats. J Pharm Sci 76:862–5
   PubMedGoogle Scholar
• Isanta JR, Lasheras B, Fos D, Cenarruzabeitia E. (1987b). Kinetics of pharmacological effect of diltiazem in spontaneous hypertensive rats. Methods Find Exp Clin Pharmacol 9:661–7
   PubMedGoogle Scholar
• Jang SH, Lee MH, Lee MG. (1994a). Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. J Pharm Sci 83:8101–4
   Google Scholar
• Jang SH, Lee MG, Kim ND. (1994b). Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA–salt-induced hypertensive rats. Biopharm Drug Dispos 15:185–206
   PubMedGoogle Scholar
• Kates RE. (1983). Calcium antagonists. Pharmacokinetic properties. Drugs 25:113–24
   PubMedGoogle Scholar
• Kato T, Kassab S, Wilkins FC Jr., et al. (1995). Endothelin antagonists improve renal function in spontaneously hypertensive rats. Hypertension 25:883–7
   PubMed Web of Science ®Google Scholar
• Kim SH, Lee MG. (1993). Influence of protein and calorie malnutrition on the pharmacokinetics and pharmacodynamics of bumetanide in rats. J Pharm Sci 82:838–43
   PubMedGoogle Scholar
• Kim EJ, Lee MG. (2001). Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm Drug Dispos 22:147–56
   PubMedGoogle Scholar
• Kim SH, Choi YM, Lee MG. (1993). Pharmacokinetics and pharmacodynamics of furosemide in protein–calorie malnutrition. J Pharmacokinet Biopharm 21:1–17
   PubMedGoogle Scholar
• Kim JY, Kim GW, Choi SH, et al. (1996a). Renal dehydropeptidase-I (DHP-I) stability and pharmacokinetics of DA-1131, a new carbapenem antibiotic. Abstracts of the Annual Meeting of the Korea Society of Applied Pharmacology; Seoul National University, Seoul, Korea
   Google Scholar
• Kim YG, Yoon EJ, Yoon WH, et al. (1996b). Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to uranyl nitrate-induced acute renal failure rats or protein–calorie malnutrition rats. Biopharm Drug Dispos 17:183–95
   PubMedGoogle Scholar
• Kim SH, Kwon JW, Kim WB, Lee MG. (1999a). Effects of cilastatin on the pharmacokinetics of a new carbapenem, DA-1131, in rats, rabbits, and dogs. Antimicrob Agents Chemother 43:2524–7
   PubMedGoogle Scholar
• Kim SH, Kim WB, Lee MG. (1999b). Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate–salt-induced hypertensive rats. Drug Metab Dispos 27:710–16
   PubMedGoogle Scholar
• Kim J, Kim EJ, Han KS, et al. (1999c). Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats. J Pharm Pharmacol 51:1031–6
   PubMedGoogle Scholar
• Kim EJ, Han KS, Lee MG. (2000a). Intestinal first-pass effect of bumetanide in rats. Int J Pharm 194:193–9
   PubMedGoogle Scholar
• Kim HJ, Han KS, Kim YG, et al. (2000b). Pharmacokinetics of a new proton pump inhibitor, YJA-20379-8, after intravenous and oral administration to spontaneously hypertensive rats and DOCA–salt-induced hypertensive rats. Biopharm Drug Dispos 21:293–302
   PubMedGoogle Scholar
• Kim EJ, Han KS, Lee MG. (2000c). Gastrointestinal first-pass effect of furosemide in rats. J Pharm Pharmacol 52:1337–43
   PubMed Web of Science ®Google Scholar
• Kim YC, Shim HJ, Lee JH, et al. (2005a). Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. Biopharm Drug Dispos 26:233–41
   PubMed Web of Science ®Google Scholar
• Kim YC, Shim HJ, Lee JH, et al. (2005b). Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA–salt-induced hypertensive rats. Biopharm Drug Dispos 26:309–20
   PubMedGoogle Scholar
• Kobrin I, Pegram BL, Frohlich ED. (1985). Acute pressure increase and intrarenal hemodynamics in conscious WKY and SHR rats. Am J Physiol 249:H1114–18
   Google Scholar
• Komura H, Iwaki M. (2005). Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. J Pharm Sci 94:397–408
   PubMed Web of Science ®Google Scholar
• Kropp H, Sundelof JG, Hajdu R, Kahan FM. (1982). Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother 22:62–70
   PubMed Web of Science ®Google Scholar
• Lee YS. (2010). Pharmacokinetics in various disease models and drug interaction with nitroglycerin of mirodenafil in rats [PhD thesis]. Seoul, South Korea: Seoul National University
   Google Scholar
• Lee MG, Chiou WL. (1983). Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623–40
   PubMedGoogle Scholar
• Lee YH, Lee MH, Shim C-K. (1992). Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure. Pharm Res 9:1599–606
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee MG, Kim ND. (1994). Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments. J Pharmacokinet Biopharm 22:1–17
   PubMedGoogle Scholar
• Lee YS, Choi YH, Yoon IS, et al. (2011). Pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, in spontaneously or DOCA–salt-induced hypertensive rats. Biopharm Drug Dispos 32:38–49
   PubMedGoogle Scholar
• LeRoy S, Berner B. (1991). Steady-state pharmacokinetics and pharmacodynamics of benazeprilat in spontaneously hypertensive rats (SHR) and Wistar–Kyoto (WKY) rats. Pharm Res 8:883–7
   PubMedGoogle Scholar
• Lewis DFV. (1996). Cytochromes P450 structure, function and mechanism. Bristol, PA: Taylor & Francis
   Google Scholar
• Lokhandwala MF, Eikenburg DC. (1983). Presynaptic receptors and alterations in norepinephrine release in spontaneously hypertensive rats. Life Sci 33:1527–42
   PubMedGoogle Scholar
• Mitruka BM, Rawnsley HM. (1981). Clinical biochemical and hematological reference values in normal experimental animals and normal humans. 2nd edition. New York (NY): Masson Publishing. USA Inc
   Google Scholar
• Nardi R, Sawa H, Carretta R, et al. (1980). Characteristic variation in electrophoretic pattern of plasma proteins in essential hypertension. Lancet II:182–3
   Google Scholar
• Nardi R, Rutsaert R, Carretta R, et al. (1981). Characteristic variation in the plasma proteins in essential hypertension. Clin Exp Hypertens 3:775–81
   PubMed Web of Science ®Google Scholar
• Nelson KM, Sheperd RE, Spitzer JA. (1987). Lipolysis and beta-adrenergic receptor binding on adipocytes of spontaneously hypertensive rats. Biochem Med Metab Biol 37:51–60
   PubMedGoogle Scholar
• Norman RA Jr., Enobakhare JA, DeClue JW, et al. (1978). Arterial pressure-urinary output relationship in hypertensive rats. Am J Physiol 234:R98–103
   PubMed Web of Science ®Google Scholar
• Ohnishi N, Kusuhara M, Yoshioka M, et al. (2003). Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 26:1315–20
   PubMed Web of Science ®Google Scholar
• Okamoto K, Aoki K. (1963). Development of a strain of spontaneously hypertensive rat. Jap Circ J 27:282–93
   PubMedGoogle Scholar
• Park JH, Lee WI, Yoon WH, et al. (1998). Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. Biopharm Drug Dispos 19:357–64
   PubMedGoogle Scholar
• Pinho MJ, Pinto V, Serrão MP, et al. (2007). Underexpression of the Na+-dependent neutral amino acid transporter ASCT2 in the spontaneously hypertensive rat kidney. Am J Physiol Regul Integr Comp Physiol 293:R538–47
   PubMed Web of Science ®Google Scholar
• Prandota J, Pruitt AW. (1975). Furosemide binding to human albumin and plasma of nephrotic children. Clin Pharmacol Ther 17:159–65
   PubMed Web of Science ®Google Scholar
• Rane A, Wilkinson GR, Shand DG. (1977). Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther 200:420–4
   PubMed Web of Science ®Google Scholar
• Roman RJ. (1987). Altered pressure-natriuresis relationship in young spontaneously hypertensive rats. Hypertension 9:III30–6
   Google Scholar
• Roman RJ, Cowley AW Jr. (1985). Abnormal pressure-diuresis-natriuresis response in spontaneously hypertensive rats. Am J Physiol 248:F199–205
   PubMed Web of Science ®Google Scholar
• Roman RJ, Kaldunski ML, Mattson DL, et al. (1988). Influence of eicosanoids on renal function of DOCA–salt hypertensive rats. Hypertension 12:287–94
   PubMedGoogle Scholar
• Russo HF, Wright LD, Skeggs HR, et al. (1947). Renal clearance of essential amino acids: threonine and phenylalanine. Proc Soc Exp Biol Med 65:215–17
   PubMedGoogle Scholar
• Ryan DE, Levin W. (1990). Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol Ther 45:153–239
   PubMed Web of Science ®Google Scholar
• Sakane Y, Berry C, Hopkins MF, et al. (1993). Disposition of thiorphan in DOCA–salt and spontaneously hypertensive rats. Res Commun Chem Pathol Pharmacol 81:151–8
   PubMedGoogle Scholar
• Shim HJ, Lee MG, Lee MH. (1991). Factors influencing the protein binding of bumetanide using an equilibrium dialysis technique. J Clin Pharm Ther 16:467–76
   PubMedGoogle Scholar
• Shim HJ, Kim YC, Park KJ, et al. (2003). Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. J Pharm Sci 92:2185–95
   PubMed Web of Science ®Google Scholar
• Sonalker PA, Tofovic SP, Jacson EK. (2004). Increased expression of the sodium transporter BSC-1 in spontaneously hypertensive rats. J Pharmacol Exp Ther 311:1052–61
   PubMed Web of Science ®Google Scholar
• Soro A, Panarelli M, Holloway CD, et al. (1995). Effects of the glucocorticoid antagonist RU486 in spontaneously hypertensive and Sprague Dawley rats. J Endocrinol Invest 18:833–9
   PubMedGoogle Scholar
• Spitzer JA, Burns AH, O'Malley PJ. (1985). Catecholamine-stimulated lipolysis in adipocytes of spontaneously hypertensive rats. Biochem Med 34:100–6
   PubMedGoogle Scholar
• Susic D, Varagic J, Frohlich ED. (2001). Abnormal renal vascular responses to dipyridamole-induced vasodilation in spontaneously hypertensive rats. Hypertension 37:894–7
   PubMedGoogle Scholar
• Tsui BCH. (1991). Pharmacokinetics and pharmacodynamics of diltiazem and its metabolites [MSc thesis]. Halifax, Nova Scotia, Canada
   Google Scholar
• Vainionpää V, Heikkinen ER, Vapaatalo H. (1974). Drug metabolism in spontaneously hypertensive rats. Pharmacol Res Commun 6:343–6
   PubMedGoogle Scholar
• Vermeulen NPE, Danhof M, Setiawan I (Thio TH), Breimer DD. (1983). Disposition of hexobarbital in the rat. Estimation of “first-pass” elimination and influence of ether anesthesia. J Pharmacol Exp Ther 226:201–5
   Google Scholar
• Watanabe T, Maeda K, Kondo T, et al. (2009). Prediction of the hepatic and renal clearance of transporter substances in rats using in vitro uptake experiments. Drug Metab Dispos 37:1471–9
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. (1975). A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377–90
   PubMed Web of Science ®Google Scholar
• Willis LR, Queener SF. (1977). Pentobarbital sleeping time and waking blood levels in spontaneously hypertensive rats. Can J Physiol Pharmacol 55:1205–7
   PubMedGoogle Scholar
• Yamori Y, Okamoto K. (1973). Spontaneous hypertension in rats versus essential hypertension in man. Singapore Med J 14:393–4
   PubMedGoogle Scholar
• Yang R, Ogasawara AK, Zioncheck TF, et al. (2002). Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 39:815–20
   PubMedGoogle Scholar
• Yang LE, Leong PKK, McDonough AA. (2007). Reducing blood pressure in SHR with enalapril provokes redistribution of NHE3, NaPi2, and NCC and decreases NaPi2 and ACE abundance. Am J Physiol Renal Physiol 293:F1197–208
   PubMed Web of Science ®Google Scholar
• Yang KH, Choi YH, Lee U, et al. (2008). Effects of cytochrome P450 inducers and inhibitors on the pharmacokinetics of intravenous furosemide in rats: involvement of CYP2C11, 2E1, 3A1, and 3A2 in furosemide metabolism. J Pharm Pharmacol 61:1–8
   Google Scholar
• Yeung PKF, Alcos A, Tang J, Casley WI. (2008). Pharmacokinetics and metabolism of diltiazem following multiple doses: comparing normotensive rat versus hypertensive rat models in vivo. Drug Metab Lett 2:146–50
   PubMedGoogle Scholar
• Yoon EJ, Lee ED, Yoon WH, et al. (1994). Pharmacokinetics, tissue distribution, and biliary excretion of FT-ADM after intravenous administration of DA-125, a prodrug of FT-ADM to dogs. A new adriamycin analog containing fluorine. Int J Pharm 109:181–7
   Google Scholar
• Yoon EJ, Shim HJ, Lee JJ, et al. (1997). Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA–salt-induced hypertensive rats. Drug Metab Dispos 25:66–74
   PubMedGoogle Scholar
• Yoon I-S, Choi M-K, Kim JS, et al. (2011). Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol. Xenobiotica 41:243–51
   PubMed Web of Science ®Google Scholar
• Zhao GS, Yuan XY, Gong BO. (1990). Correlation analysis of serum amino-acid and blood pressure 8 Chinese populations. Acta Nutriment Sin 12:355–61
   Google Scholar
• Zhao G, Li Z, Gu T. (2001a). Antihypertension and anti-cardiovascular remodeling by phenylalanine in spontaneously hypertensive rats: effectiveness and mechanisms. Chin Med J 114:270–4
   PubMedGoogle Scholar
• Zhao G, Gu T, Li Z. (2001b). Inherited disturbances of phenylalanine metabolic kinetics in essential hypertension. Chin Med J 114:799–802
   PubMedGoogle Scholar